Discovery of tetralin ureas as potent melanin concentrating hormone 1 receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 6, 2007, Pages 1718-1721

  Guo, Tao ^a   Gu, Huizhong ^a   Hobbs, Doug W ^a   Busler, Dennis E ^a   Rokosz, Laura L ^a  

^a PHARMACOPEIA INC   (United States)

Author keywords

MCH; MCH1R antagonists; Obesity

Indexed keywords

HORMONE RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; MELANIN CONCENTRATING HORMONE; MELANIN CONCENTRATING HORMONE 1 RECEPTOR; MELANIN CONCENTRATING HORMONE 1 RECEPTOR ANTAGONIST; TETRALIN DERIVATIVE; UNCLASSIFIED DRUG; UREA DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENERGY BALANCE; FOOD INTAKE; HYDROGENATION; MAMMAL; MOUSE; NONHUMAN; OBESITY; RAT;

ANIMALS; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DESIGN; HUMANS; MICE; MICE, KNOCKOUT; RATS; RECEPTORS, SOMATOSTATIN; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDRONAPHTHALENES; TISSUE DISTRIBUTION; UREA;

MAMMALIA; MUS;

EID: 33847039872     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.12.080     Document Type: Article

References (25)

1. Hervieu G.J. Expert. Opin. Ther. Targets 10 (2006) 211
2. Rossi M., Choi S.J., O'Shea D., Miyoshi T., Ghatei M.A., and Bloom S.R. Endocrinology 138 (1997) 351
3. Ludwig D.S., Tritos N.A., Mastaitis J.W., Kulkarni R., Kokkotou E., Elmquist J., Lowell B., Flier J.S., and Maratos-Flier E. J. Clin. Invest. 107 (2001) 379
4. Shimada M., Tritos N.A., Lowell B.B., Flier J.S., and Maratos-Flier E. Nature 396 (1998) 670
5. Chamber J., Ames R.S., Bergsma D., Muir A., Fitzgerald L.R., Hervieu G., Dytko G.M., Foley J.J., Martin J., Liu W.S., Park J., et al. Nature 400 (1999) 261
6. Saito Y., Nothacker H.P., Wang Z., Lin S.H., Leslie F., and Civelli O. Nature 400 (1999) 265
7. Hill J., Duckworth M., Murdock P., Rennie G., Sabido-David C., Ames R.S., Szekeres P., Wilson S., Bergsma D.J., Gloger I.S., Levy D.S., et al. J. Biol. Chem. 276 (2001) 20125
8. Sailer A.W., Sano H., Zeng Z., McDonald T.P., Pan J., Pong S.S., Feighner S.D., Tan C.P., Fukami T., Iwaasa H., Hreniuk D.L., et al. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 7564
9. Chen Y., Hu C., Hsu C.K., Zhang Q., Bi C., Asnicar M., Hsiung H.M., Fox N., Slieker L.J., Yang D.D., Heiman M.L., and Shi Y. Endocrinology 143 (2002) 2469
10. Marsh D.J., Weingarth D.T., Novi D.E., Chen H.Y., Trumbauer M.E., Chen A.S., Guan X.M., Jiang M.M., Feng Y., Camacho R.E., et al. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 3240
11. For reviews of small molecule MCH1R antagonists, see:. Rokosz L.L., and Hobbs D.W. Drug News Perspect. 19 (2006) 273
12. Handlon A.L., and Zhou H. J. Med. Chem. 49 (2006) 4017
13. Kowalski T.J., and McBriar M.D. Annu. Rep. Med. Chem. 40 (2005) 119
14. Dyke H.J., and Ray N.C. Expert Opin. Ther. Patents 15 (2005) 1303
15. Guo T., Hunter R.C., Gu H., Rokosz L.L., Stauffer T.M., and Hobbs D.W. Bioorg. Med. Chem. Lett. 15 (2005) 3691
16. Guo T., Shao Y., Qian G., Rokosz L.L., Stauffer T.M., Hunter R.C., Babu S.D., Gu H., and Hobbs D.W. Bioorg. Med. Chem. Lett. 15 (2005) 3696
17. Palani A., Shapiro S., McBriar M.D., Clader J.W., Greenlee W.J., Spar B., Kowalski T.J., Farley C., Cook J., van Heek M., Weig B., O'Neill K., Graziano M., and Hawes B.E. J. Med. Chem. 48 (2005) 4746
18. Xu R., Li S., Paruchova J., McBriar M.D., Guzik H., Palani A., Clader J.W., Cox K., Greenlee W.J., Hawes B.E., Kowalski T.J., O'Neill K., Spar B., Weig B., and Weston D.J. Bioorg. Med. Chem. 14 (2006) 3285
19. McBriar M.D., Guzik H., Xu R., Paruchova J., Li S., Palani A., Clader J.W., Greenlee W.J., Hawes B.E., Kowalski T.J., O'Neill K., Spar B., and Weig B. J. Med. Chem. 48 (2005) 2274
20. McBriar M.D., Guzik H., Shapiro S., Paruchova J., Xu R., Palani A., Clader J.W., Cox K., Greenlee W.J., Hawes B.E., Kowalski T.J., O'Neill K., Spar B., Weig B., Weston D.J., Farley C., and Cook J. J. Med. Chem. 49 (2006) 2294
21. McBriar M.D., Guzik H., Shapiro S., Xu R., Paruchova J., Clader J.W., O'Neill K., Hawes B.E., Sorota S., Margulis M., Tucker K., Weston D.J., and Cox K. Bioorg. Med. Chem. Lett. 16 (2006) 4262
22. is represent the average of two or more determinations. The standard deviations were not greater than 50% from the mean.
23. Korfmacher W.A., Cox K.A., Ng K.J., Veals J., Hsien Y., Wainhaus S., Broske L., Prelusky D., Nomeir A., and White R.E. Rapid Commun. Mass Spectrom. 15 (2001) 335
24. 10 for 30 min. The sections were then rinsed with binding buffer and dried. The amount of radiolabeled MCH-ADO that remained bound to the brain section following washing was specific to MCH binding sites. Addition of nonlabeled MCH to the binding reaction completely abolished radiolabeled MCH-ADO binding to the brain section. Radioactivity bound to the section was quantified using a Storm 860 phosphorimager. Hawes B.E., Green B., O'Neill K., Fried S., and Graziano M.P. Endocrinology 141 (2000) 4524
25. Audinot V., Lahaye C., Suply T., Beauverger P., Rodriguez M., Galizzi J.P., Fauchere J.L., and Boutin J.A. Br. J. Pharmacol. 133 (2001) 371